Customer outreach and other marketing efforts may be starting to pay off for Biosphere Medical Inc.

The Rockland, Mass.-based maker of microscopic polymer beads reported $8.1 million in sales during the three months ended June 30, with a 13 percent jump in U.S. sales of the company’s interventional gynecology products pacing much of that gain.

The net loss for the period was $677,000, which compares with a $1.3 million loss on $7.6 million in sales during the June 2008 quarter.

Hologic Inc. said 1 million women have undergone its NovaSure global endometrial ablation treatment.

The system is used to treat menorrhagia, or heavy menstrual bleeding, using a 90-second burst of low-frequency radio energy in a roughly 5-minute outpatient procedure.

The Bedford, Mass.-based women’s health products maker said U.S. physicians performed about 312,000 GEA procedures last year, about 205,000 using the NovaSure device, making Hologic’s market share roughly 66 percent.

The Food & Drug Administration gave the nod to Hologic Inc.‘s Adiana sterilization treatment, which uses a minimally invasive natural orifice surgical technique to provide permanent contraception.

The Bedford women’s health products maker said the the federal safety monitor gave pre-market approval for procedure, which involves threading an endoscope through the vagina, cervix and uterus into the fallopian tubes, where radiofrequency energy is applied to small sections of the tube.

Interlace Medical Inc. raised nearly $21 million to begin commercializing its MyoSure minimally invasive system to remove intrauterine fibroids and polyps with an outpatient treatment.

The Framingham-based company raised the Series C round from Baird Venture Partners, Boston-based HLM Venture Partners, Hambrecht & Quist Capital Management LLC and Aperture Venture Partners.